Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine, has closed a US$115 million Series B financing round.
The financing was led by Dimension Capital (Dimension), a multistage investment firm dedicated to the interface of technology and the life sciences, with participation from existing and new investors including Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund: A Breakthrough T1D Venture.
Fasken advised Dimension with a team led by Jon Conlin (Technology), and included Lindsay Clark (Technology) and Sarina Trasolini (Technology).
Jurisdiction
- British Columbia
